To identify novel necroptosis inhibitors for potential clinical application, we screened the FDA-approved drug library using a well-established necroptosis model in mouse fibrosarcoma L929 cells (Fig. 1A), which are sensitive to TNFα-induced necroptosis even in the absence of caspase inhibitors [6, 25]. The gene discussed is TNF; the disease is fibrosarcoma.